Foliglurax
Chemical compound
Clinical data | |
---|---|
Other names | DT2331; PXT-002331; PXT-2331 |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
Chemical and physical data | |
Formula | C23H23N3O3S |
Molar mass | 421.52 g·mol−1 |
3D model (JSmol) |
|
| |
InChI
|
Foliglurax (developmental code names PXT-002331, DT2331) is a positive allosteric modulator of the metabotropic glutamate receptor 4 (mGluR4),[1] which is under development by Prexton Therapeutics for the treatment of Parkinson's disease.[2][3][4] It reached phase II clinical trials,[2] but while it was found to be safe and showed some signs of clinical improvement, it failed to sufficiently distinguish itself from placebo to meet the study endpoints.[5][6]
References
- ^ Charvin D, Pomel V, Ortiz M, Frauli M, Scheffler S, Steinberg E, et al. (October 2017). "Discovery, Structure-Activity Relationship, and Antiparkinsonian Effect of a Potent and Brain-Penetrant Chemical Series of Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4". Journal of Medicinal Chemistry. 60 (20): 8515–8537. doi:10.1021/acs.jmedchem.7b00991. PMID 28902994.
- ^ a b "Foliglurax - Lundbeck". Adis Insight. Springer Nature Switzerland AG.
- ^ Jankovic J, Aguilar LG (August 2008). "Current approaches to the treatment of Parkinson's disease". Neuropsychiatric Disease and Treatment. 4 (4): 743–57. doi:10.1016/j.bmcl.2017.07.075. PMC 2536542. PMID 19043519.
- ^ Volpi C, Fallarino F, Mondanelli G, Macchiarulo A, Grohmann U (May 2018). "Opportunities and challenges in drug discovery targeting metabotropic glutamate receptor 4". Expert Opinion on Drug Discovery. 13 (5): 411–423. doi:10.1080/17460441.2018.1443076. PMID 29486616. S2CID 4572251.
- ^ Gonzalez-Latapi P, Bhowmick SS, Saranza G, Fox SH (October 2020). "Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update". CNS Drugs. 34 (10): 1025–1044. doi:10.1007/s40263-020-00754-0. PMID 32785890. S2CID 221111043.
- ^ Rascol O, Medori R, Baayen C, Such P, Meulien D (February 2022). "A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease". Movement Disorders. 37 (5): 1088–1093. doi:10.1002/mds.28970. PMC 9303267. PMID 35218231. S2CID 247129161.
- v
- t
- e
Metabotropic glutamate receptor modulators
mGluR1Tooltip Metabotropic glutamate receptor 1 |
|
---|---|
mGluR5Tooltip Metabotropic glutamate receptor 5 |
|
mGluR2Tooltip Metabotropic glutamate receptor 2 |
|
---|---|
mGluR3Tooltip Metabotropic glutamate receptor 3 |
|
mGluR4Tooltip Metabotropic glutamate receptor 4 | |
---|---|
mGluR6Tooltip Metabotropic glutamate receptor 6 |
|
mGluR7Tooltip Metabotropic glutamate receptor 7 | |
mGluR8Tooltip Metabotropic glutamate receptor 8 |
|
See also: Receptor/signaling modulators • Ionotropic glutamate receptor modulators • Glutamate metabolism/transport modulators
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e